我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
13
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
8
61.5%
招募中
2
15.4%
终止
1
7.7%
Unknown
暂无批准数据
- Valbiotis' Lipridrive met its primary endpoint in a Phase II/III trial, significantly reducing LDL cholesterol in patients with mild to moderate hypercholesterolemia. - The international, multicenter, randomized, placebo-controlled study involved 180 subjects receiving a 5g daily dose of Lipridrive over three months. - Lipidrive showed excellent safety and tolerability, with compliance exceeding 98%, reinforcing its potential as a well-received therapeutic option. - Full results from the HEART II study will be presented at international congresses and published in peer-reviewed journals.
